T. Rowe Price Investment Management Portfolio holdings
T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Roper Technologies
ROP
|
+$840M |
| 2 |
Cigna
CI
|
+$836M |
| 3 |
Thermo Fisher Scientific
TMO
|
+$788M |
| 4 |
Abbott
ABT
|
+$766M |
| 5 |
Becton Dickinson
BDX
|
+$743M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Salesforce
CRM
|
+$1.26B |
| 2 |
Martin Marietta Materials
MLM
|
+$1.05B |
| 3 |
Linde
LIN
|
+$913M |
| 4 |
Intercontinental Exchange
ICE
|
+$865M |
| 5 |
AbbVie
ABBV
|
+$857M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.45% |
| 2 | Healthcare | 20.82% |
| 3 | Consumer Discretionary | 13.33% |
| 4 | Industrials | 10.66% |
| 5 | Financials | 10.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
SLB Ltd
SLB
$77.3B
| $4.94M | ﹤0.01% |
128,821
+42,585
| +49% | +$1.79M |
|
577
Cencora
COR
$59.8B
| $4.91M | ﹤0.01% |
+21,871
| New | +$5.14M |
|
|
APLT
578
DELISTED
Applied Therapeutics
APLT
| $4.64M | ﹤0.01% |
5,420,920
+5,213,370
| +2,512% | +$32.7M |
|
579
Guidewire Software
GWRE
$14.5B
| $4.5M | ﹤0.01% |
+26,700
| New | +$4.99M |
|
|
BBOT
580
BridgeBio Oncology
BBOT
$760M
| $4.2M | ﹤0.01% |
400,247
+2,598
| +0.7% | +$27.3K |
|
581
WEC Energy
WEC
$35.8B
| $4.09M | ﹤0.01% |
43,528
+8,009
| +23% | +$777K |
|
582
KLA
KLAC
$276B
| $3.59M | ﹤0.01% |
56,900
+19,750
| +53% | +$1.33M |
|
|
INFA
583
DELISTED
Informatica
INFA
| $3.58M | ﹤0.01% |
137,975
+45,455
| +49% | +$1.19M |
|
584
Floor & Decor
FND
$6.32B
| $3.4M | ﹤0.01% |
34,057
-391,952
| -92% | -$42.1M |
|
585
Xcel Energy
XEL
$49.4B
| $3.25M | ﹤0.01% |
48,201
+9,428
| +24% | +$632K |
|
586
Grocery Outlet
GO
$1.05B
| $3.04M | ﹤0.01% |
+194,551
| New | +$3.38M |
|
587
Toro Company
TTC
$9.27B
| $2.7M | ﹤0.01% |
33,695
-203,330
| -86% | -$17M |
|
588
RxSight
RXST
$289M
| $2.51M | ﹤0.01% |
73,027
-3,006
| -4% | -$136K |
|
589
AppFolio
APPF
$6.92B
| $2.14M | ﹤0.01% |
8,672
-77,452
| -90% | -$18.1M |
|
590
JPMorgan Chase
JPM
$965B
| $1.95M | ﹤0.01% |
8,139
-137
| -2% | -$31.9K |
|
591
Fabrinet
FN
$20.7B
| $1.95M | ﹤0.01% |
+8,844
| New | +$2.13M |
|
592
Jasper Therapeutics
JSPR
$28.6M
| $1.76M | ﹤0.01% |
+82,165
| New | +$1.71M |
|
593
Robert Half
RHI
$4.27B
| $1.67M | ﹤0.01% |
+23,664
| New | +$1.69M |
|
594
EyePoint Inc
EYPT
$1.16B
| $1.54M | ﹤0.01% |
206,939
-1,061,815
| -84% | -$9.88M |
|
|
APLS
595
DELISTED
Apellis Pharmaceuticals
APLS
| $1.52M | ﹤0.01% |
47,713
-2,937,559
| -98% | -$88.3M |
|
|
LB
596
LandBridge Co
LB
$2.1B
| $1.43M | ﹤0.01% |
+22,137
| New | +$1.33M |
|
597
S&P Global
SPGI
$122B
| $1.29M | ﹤0.01% |
2,598
-6,685
| -72% | -$3.39M |
|
598
Procter & Gamble
PG
$336B
| $1.26M | ﹤0.01% |
7,494
+248
| +3% | +$42.2K |
|
599
ExxonMobil
XOM
$656B
| $1.18M | ﹤0.01% |
10,985
| – | – |
|
600
Bank of America
BAC
$448B
| $1.08M | ﹤0.01% |
24,506
-3,533
| -13% | -$155K |
|
Similar funds
T. Rowe Price Investment Management's Q4 2024 Portfolio in Review
As of Q4 2024, T. Rowe Price Investment Management held 684 positions worth $162B, down 2.2% from $166B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
T. Rowe Price Investment Management's Q4 2024 filing shows 61 new, 276 increased, 294 reduced and 51 closed positions. Its largest new stake was Cigna: 2,623,729 shares worth $725M. The largest sale was Salesforce, an estimated $1.26B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Investment Management's largest Q4 2024 buy was Cigna: 2,623,729 shares worth $725M.
- T. Rowe Price Investment Management added most to Roper Technologies in Q4 2024, an estimated $840M increase.
- T. Rowe Price Investment Management's biggest Q4 2024 reduction was Salesforce, cutting an estimated $1.26B.
- T. Rowe Price Investment Management fully exited Southwestern Energy Company in Q4 2024, selling an estimated $278M.
- T. Rowe Price Investment Management's ten largest holdings make up 19% of its $162B portfolio in Q4 2024.
- T. Rowe Price Investment Management opened 61 new positions and closed 51 in Q4 2024.
- T. Rowe Price Investment Management's portfolio value fell 2.2% quarter-over-quarter to $162B.
Based on T. Rowe Price Investment Management's 13F filing for Q4 2024, filed 14 Feb 2025.